Targeting mutant KRAS

被引：16

作者：

Erlanson, Daniel A. ^{[1
]}

Webster, Kevin R. ^{[1
]}

机构：

[1] Frontier Med Corp, 151 Oyster Point Blvd,2nd Floor, San Francisco, CA 94080 USA

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 2021年 / 62卷

关键词：

KRAS;   G12C; G12D; Covalent drugs; Precision oncology; Fragment -based drug discovery; AMG; 510; INHIBITORS; KRAS(G12C); DISCOVERY;

D O I：

10.1016/j.cbpa.2021.02.010

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The protein KRAS has for decades been considered a holy grail of cancer drug discovery. For most of that time, it has also been considered undruggable. Since 2018, five compounds have entered the clinic targeting a single mutant form of KRAS, G12C. Here, we review each of these compounds along with additional approaches to targeting this and other mutants. Remaining challenges include expanding the identification of inhibitors to a broader range of known mutants and to con -formations of the protein more likely to avoid development of resistance.

引用

页码：101 / 108

页数：8

共 50 条

[31] Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway
Korzeniecki, Claudia
Priefer, Ronny
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 211
[32] Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Chunxiao Zhu
Xiaoqing Guan
Xinuo Zhang
Xin Luan
Zhengbo Song
Xiangdong Cheng
Weidong Zhang
Jiang-Jiang Qin
Molecular Cancer, 21
[33] Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down
Hobbs, G. Aaron
Wittinghofer, Alfred
Der, Channing J.
CANCER CELL, 2016, 29 (03) : 251 - 253
[34] Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer
Hiraki, Masayuki
Nishimura, Junichi
Takahashi, Hidekazu
Wu, Xin
Takahashi, Yusuke
Miyo, Masaaki
Nishida, Naohiro
Uemura, Mamoru
Hata, Taishi
Takemasa, Ichiro
Mizushima, Tsunekazu
Soh, Jae-Won
Doki, Yuichiro
Mori, Masaki
Yamamoto, Hirofumi
MOLECULAR THERAPY-NUCLEIC ACIDS, 2015, 4 : e231
[35] Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
Miyazaki, Satoru
Kitazawa, Masato
Nakamura, Satoshi
Koyama, Makoto
Yamamoto, Yuta
Hondo, Nao
Kataoka, Masahiro
Tanaka, Hirokazu
Takeoka, Michiko
Komatsu, Daisuke
Soejima, Yuji
MOLECULAR ONCOLOGY, 2025, 19 (02) : 377 - 390
[36] Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer
Leung, Elaine Lai-Han
Luo, Lian Xiang
Li, Ying
Liu, Zhong-Qiu
Li, Lan Lan
Shi, Dan Feng
Xie, Ying
Huang, Min
Lu, Lin Lin
Duan, Fu Gang
Huang, Ju Min
Fan, Xing Xing
Yuan, Zhong Wen
Ding, Jian
Yao, Xiao Jun
Ward, David C.
Liu, Liang
INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (05) : 1334 - 1345
[37] Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
Liu, Weiran
Yin, Yuesong
Wang, Jun
Shi, Bowen
Zhang, Lianmin
Qian, Dong
Li, Chenguang
Zhang, Hua
Wang, Shengguang
Zhu, Jinfang
Gao, Liuwei
Zhang, Qiang
Jia, Bin
Hao, Ligang
Wang, Changli
Zhang, Bin
ONCOTARGET, 2017, 8 (01) : 179 - 190
[38] Akt mediated ROS-dependent selective targeting of mutant KRAS tumors
Kartini, Iskandar
Majidah, Rezlan
Shazib, Pervaiz
FREE RADICAL BIOLOGY AND MEDICINE, 2014, 75 : S13 - S13
[39] Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting
Adham S. Bear
Tatiana Blanchard
Joseph Cesare
Michael J. Ford
Lee P. Richman
Chong Xu
Miren L. Baroja
Sarah McCuaig
Christina Costeas
Khatuna Gabunia
John Scholler
Avery D. Posey
Mark H. O’Hara
Anze Smole
Daniel J. Powell
Benjamin A. Garcia
Robert H. Vonderheide
Gerald P. Linette
Beatriz M. Carreno
Nature Communications, 12
[40] Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators
Wang, Yuanxiang
Kaiser, Christine E.
Frett, Brendan
Li, Hong-yu
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (13) : 5219 - 5230

← 1 2 3 4 5 →